The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution

Seminars in Immunology

Volumn 27, Issue 3, 2015, Pages 200-215

  Serhan, Charles N ^a   Chiang, Nan ^a   Dalli, Jesmond ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Essential fatty acids; Host defense; Infection; Inflammation; Lipid mediator

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 12 LIPOXYGENASE; CD11B ANTIGEN; CD59 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAPENTAENOIC ACID; EOTAXIN; KI 67 ANTIGEN; LIPID; NETRIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; AUTACOID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; LIPOXIN;

ADAPTIVE IMMUNITY; COGNITION; DENDRITIC CELL; EOSINOPHIL; HOST RESISTANCE; HUMAN; INFLAMMATION; MACROPHAGE; MYOSITIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PAIN; RESISTANCE TRAINING; REVIEW; THROMBOCYTE; TISSUE REGENERATION; WOUND HEALING; ACUTE DISEASE; ANIMAL; HOMEOSTASIS; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REPERFUSION INJURY;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIPOXINS; MICE; REPERFUSION INJURY; WOUND HEALING;

EID: 84937521269     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.03.004     Document Type: Review

References (203)

1. Serhan C.N. The resolution of inflammation: the devil in the flask and in the details. FASEB J. 2011, 25:1441-1448.
2. Samuelsson B. Role of basic science in the development of new medicines: examples from the eicosanoid field. J. Biol. Chem. 2012, 287:10070-10080.
3. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000, 192:1197-1204.
4. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 2002, 196:1025-1037.
5. Malawista S.E., de Boisfleury Chevance A., van Damme J., Serhan C.N. Tonic inhibition of chemotaxis in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17949-17954.
6. Lammermann T., Afonso P.V., Angermann B.R., Wang J.M., Kastenmuller W., Parent C.A., et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 2013, 498:371-375.
7. Buckley C.D., Gilroy D.W., Serhan C.N., Stockinger B., Tak P.P. The resolution of inflammation. Nat. Rev. Immunol. 2013, 13:59-66.
8. Robbins S.L., Cotran R. Pathologic Basis of Disease 1979, W.B. Saunders Co., Philadelphia. second ed.
9. Tauber A.I., Chernyak L. Metchnikoff and the Origins of Immunology: From Metaphor to Theory 1991, Oxford University Press, New York.
10. Norris P.C., Dennis E.A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8517-8522.
11. Dalli J., Winkler J.W., Colas R.A., Arnardottir H., Cheng C.Y.C., Chiang N., et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem. Biol. 2013, 20:188-201.
12. Dalli J., Zhu M., Vlasenko N.A., Deng B., Haeggstrom J.Z., Petasis N.A., et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 2013, 27:2573-2583.
13. Bailey R.L., Gahche J.J., Miller P.E., Thomas P.R., Dwyer J.T. Why US adults use dietary supplements. JAMA Intern. Med. 2013, 173:355-361.
14. Yates C.M., Calder P.C., Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol. Ther. 2013, 10.1016/j.pharmthera.2013.10.010.
15. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6:1191-1197.
16. Serhan C.N., Petasis N.A. Resolvins and protectins in inflammation-resolution. Chem. Rev. 2011, 111:5922-5943.
17. Miyahara T., Runge S., Chatterjee A., Chen M., Mottola G., Fitzgerald J.M., et al. D-series resolvins attenuate vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013, 27:2220-2232.
18. Serhan C.N., Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol. 2013, 13:632-640.
19. Chiu C.Y., Gomolka B., Dierkes C., Huang N.R., Schroeder M., Purschke M., et al. Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. Inflamm. Res. 2012, 61:967-976.
20. Dalli J., Colas R.A., Serhan C.N. Novel n-3 immunoresolvents: structures and actions. Sci. Rep. 2013, 3:1940.
21. Deng B., Wang C.W., Arnardottir H.H., Li Y., Cheng C.Y., Dalli J., et al. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLOS ONE 2014, 9:e102362.
22. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001, 2:612-619.
23. 4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 2000, 164:1029-1036.
24. 4 stable analogues. J. Clin. Invest. 1998, 101:819-826.
25. Chan M.M-Y., Moore A.R. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 2010, 184:6418-6426.
26. Markworth J.F., Vella L.D., Lingard B.S., Tull D.L., Rupasinghe T.W., Sinclair A.J., et al. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305:R1281-R1296.
27. Schwab J.M., Chiang N., Arita M., Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874.
28. Morris T., Stables M., Hobbs A., de Souza P., Colville-Nash P., Warner T., et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 2009, 183:2089-2096.
29. Lucas C.D., Dorward D.A., Tait M.A., Fox S., Marwick J.A., Allen K.C., et al. Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung. Mucosal Immunol. 2014, 7:857-868.
30. Levy B.D., Serhan C.N. Resolution of acute inflammation in the lung. Annu. Rev. Physiol. 2014, 76. 27.1-6.
31. Chiang N., Schwab J.M., Fredman G., Kasuga K., Gelman S., Serhan C.N. Anesthetics impact the resolution of inflammation. PLoS ONE 2008, 3:e1879.
32. Chiang N., Fredman G., Bäckhed F., Oh S.F., Vickery T.W., Schmidt B.A., et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 484:524-528.
33. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
34. Birnbaum Y., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Martinez J.D., et al. Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929-935.
35. Clària J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9475-9479.
36. Cooray S.N., Gobbetti T., Montero-Melendez T., McArthur S., Thompson D., Clark A.J., et al. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:18232-18237.
37. Serhan C.N., Fredman G., Yang R., Karamnov S., Belayev L.S., Bazan N.G., et al. Novel proresolving aspirin-triggered DHA pathway. Chem. Biol. 2011, 18:976-987.
38. 4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15178-15183.
39. Morris T., Stables M., Colville-Nash P., Newson J., Bellingan G., de Souza P.M., et al. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8842-8847.
40. Pillai P.S., Leeson S., Porter T.F., Owens C.D., Kim J.M., Conte M.S., et al. Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation 2012, 35:98-113.
41. Norling L.V., Spite M., Yang R., Flower R.J., Perretti M., Serhan C.N. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 2011, 186:5543-5547.
42. Dalli J., Serhan C.N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120:e60-e72.
43. Wang J., Byrne J.D., Napier M.E., DeSimone J.M. More effective nanomedicines through particle design. Small 2011, 7:1919-1931.
44. Van Dyke T.E., Hasturk H., Kantarci A., Freire M.O., Nguyen D., Dalli J., et al. Proresolving nanomedicines activate bone regeneration in periodontitis. J. Dent. Res. 2015, 94:148-156.
45. Jones C.N., Dalli J., Dimisko L., Wong E., Serhan C.N., Irimia D. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20560-20565.
46. Tang K., Liu J., Yang Z., Zhang B., Zhang H., Huang C., et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. Biochem. Biophys. Res. Commun. 2010, 400:432-436.
47. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
48. Stables M.J., Shah S., Camon E.B., Lovering R.C., Newson J., Bystrom J., et al. Transcriptomic analyses of murine resolution-phase macrophages. Blood 2011, 118:e192-e208.
49. Miki Y., Yamamoto K., Taketomi Y., Sato H., Shimo K., Kobayashi T., et al. Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J. Exp. Med. 2013, 210:1217-1234.
50. Miyata J., Fukunaga K., Iwamoto R., Isobe Y., Niimi K., Takamiya R., et al. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J. Allergy Clin. Immunol. 2013, 131:353-360.
51. Yamada T., Tani Y., Nakanishi H., Taguchi R., Arita M., Arai H. Eosinophils promote resolution of acute periotonitis by producing proresolving mediators in mice. FASEB J. 2011, 25:561-568.
52. Isobe Y., Arita M., Iwamoto R., Urabe D., Todoroki H., Masuda K., et al. Stereochemical assignment and anti-inflammatory properties of the omega-3 lipid mediator resolvin E3. J. Biochem. 2013, 153:355-360.
53. Arita M., Bianchini F., Aliberti J., Sher A., Chiang N., Hong S., et al. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201:713-722.
54. Ohira T., Arita M., Omori K., Recchiuti A., Van Dyke T.E., Serhan C.N. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J. Biol. Chem. 2010, 285:3451-3461.
55. El Kebir D., Gjorstrup P., Filep J.G. Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:14983-14988.
56. Krishnamoorthy S., Recchiuti A., Chiang N., Fredman G., Serhan C.N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and pro-resolving microRNAs. Am. J. Pathol. 2012, 180:2018-2027.
57. Norling L.V., Dalli J., Flower R.J., Serhan C.N., Perretti M. Resolvin D1 limits polymorphonuclear leukocytes recruitment to inflammatory loci: receptor dependent actions. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1970-1978.
58. Fredman G., Li Y., Dalli J., Chiang N., Serhan C.N. Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci. Rep. 2012, 2:639.
59. Li Y., Dalli J., Chiang N., Baron R.M., Quintana C., Serhan C.N. Plasticity of leukocytic exudates in resolving acute inflammation is regulated by microRNA and proresolving mediators. Immunity 2013, 39:885-898.
60. Li D., Hodges R.R., Jiao J., Carozza R.B., Shatos M.A., Chiang N., et al. Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol. 2013, 6:1119-1130.
61. Nelson J., Leigh N.J., Mellas R.E., McCall A.D., Aguirre A., Baker O.J. The ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands. Am. J. Physiol. Cell Physiol. 2013, 10.1152/ajpcell.00284.2013.
62. Simiele F., Recchiuti A., Mattoscio D., De Luca A., Cianci E., Franchi S., et al. Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity. FASEB J. 2012, 26:1323-1333.
63. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
64. Gilbertson T.A., Khan N.A. Cell signaling mechanisms of oro-gustatory detection of dietary fat: advances and challenges. Prog. Lipid Res. 2014, 53:82-92.
65. Sun Q., Hirasawa A., Hara T., Kimura I., Adachi T., Awaji T., et al. Structure-activity relationships of GPR120 agonists based on a docking simulation. Mol. Pharmacol. 2010, 78:804-810.
66. Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014, 510:92-101.
67. Serhan C.N., Jain A., Marleau S., Clish C., Kantarci A., Behbehani B., et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 2003, 171:6856-6865.
68. Hasturk H., Kantarci A., Goguet-Surmenian E., Blackwood A., Andry C., Serhan C.N., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 2007, 179:7021-7029.
69. Fullerton J.N., O'Brien A.J., Gilroy D.W. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol. 2014, 35:12-21.
70. Oh S.F., Pillai P.S., Recchiuti A., Yang R., Serhan C.N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 2011, 121:569-581.
71. Walker J., Dichter E., Lacorte G., Kerner D., Spur B., Rodriguez A., et al. Lipoxin A4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 2011, 36:410-416.
72. Prescott D., McKay D.M. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G487-G497.
73. Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 2009, 10:899-906.
74. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
75. Rajasagi N.K., Reddy P.B., Mulik S., Gjorstrup P., Rouse B.T. Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology. Invest. Ophthalmol. Vis. Sci. 2013, 54:6269-6279.
76. Rajasagi N.K., Reddy P.B.J., Suryawanshi A., Mulik S., Gjorstrup P., Rouse B.T. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J. Immunol. 2011, 186:1735-1746.
77. Cilloniz C., Pantin-Jackwood M.J., Ni C., Goodman A.G., Peng X., Proll S.C., et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J. Virol. 2010, 84:7613-7624.
78. Morita M., Kuba K., Ichikawa A., Nakayama M., Katahira J., Iwamoto R., et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 2013, 153:112-125.
79. Tam V.C., Quehenberger O., Oshansky C.M., Suen R., Armando A.M., Treuting P.M., et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 2013, 154:213-227.
80. 4 in children with acute poststreptococcal glomerulonephritis. Am. J. Pathol. 2009, 174:115-122.
81. Haas-Stapleton E.H., Lu Y., Hong S., Arita M., Favoreto S., Nigam S., et al. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. PLoS ONE 2007, 2:e1316.
82. -/- mice. Blood 2014, 124:2847-2857.
83. Baillie J.K., Digard P. Influenza - time to target the host. N. Engl. J. Med. 2013, 369:191-193.
84. Wang S.B., Hu K.M., Seamon K.J., Mani V., Chen Y., Gronert K. Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J. 2012, 26:1506-1516.
85. Menon R. The Effect of Resolvins on Dermal Wound Healing 2012, Rutgers, New Brunswick, NJ.
86. Tang Y., Zhang M.J., Hellmann J., Kosuri M., Bhatnagar A., Spite M. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 2013, 62:618-627.
87. Spite M., Claria J., Serhan C.N. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2013, 19:21-36.
88. Hong S., Gronert K., Devchand P., Moussignac R.-L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 2003, 278:14677-14687.
89. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115:2774-2783.
90. Hong S., Tjonahen E., Morgan E.L., Yu L., Serhan C.N., Rowley A.F. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins - mediator lipidomic analysis. Prostaglandins Other Lipid Mediat. 2005, 78:107-116.
91. Marcheselli V.L., Hong S., Lukiw W.J., Hua Tian X., Gronert K., Musto A., et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 2003, 278:43807-43817.
92. Bazan N.G., Calandria J.M., Serhan C.N. Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J. Lipid Res. 2010, 51:2018-2031.
93. Sheets K.G., Jun B., Zhou Y., Zhu M., Petasis N.A., Gordon W.C., et al. Microglial ramification and redistribution concomitant with the attenuation of choroidal neovascularization by neuroprotectin D1. Mol. Vis. 2013, 19:1747-1759.
94. Bazan N.G., Eady T.N., Khoutorova L., Atkins K.D., Hong S., Lu Y., et al. Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp. Neurol. 2012, 236:122-130.
95. Murphy E.J. A lipid neurochemist's siren: docosahexaenoic acid and its elusive function in the central nervous system. J. Neurochem. 2013, 127:299-302.
96. Wang X., Zhu M., Hjorth E., Cortés-Toro V., Eyjolfsdottir H., Graff C., et al. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 2014, 10.1016/j.jalz.2013.12.024.
97. Mizwicki M.T., Liu G., Fiala M., Magpantay L., Sayre J., Siani A., et al. 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's Disease patients. J. Alzheimers Dis. 2013, 34:155-170.
98. Liu G., Fiala M., Mizwicki M.T., Sayre J., Magpantay L., Siani A., et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis. 2012, 1:60-74.
99. Wu Y., Ye X.H., Guo P.P., Xu S.P., Wang J., Yuan S.Y., et al. Neuroprotective effect of lipoxin A4 methyl ester in a rat model of permanent focal cerebral ischemia. J. Mol. Neurosci. 2010, 42:226-234.
100. Wu J., Wang A., Min Z., Xiong Y., Yan Q., Zhang J., et al. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo. Biochem. Biophys. Res. Commun. 2011, 408:382-387.
101. Wu L., Miao S., Zou L.B., Wu P., Hao H., Tang K., et al. Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury. J. Mol. Neurosci. 2012, 48:185-200.
102. 4 analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res. 2010, 1323:174-183.
103. 4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci. 2009, 29:3875-3884.
104. Wu L., Liu Z.J., Miao S., Zou L.B., Cai L., Wu P., et al. Lipoxin A4 ameliorates cerebral ischaemia/reperfusion injury through upregulation of nuclear factor erythroid 2-related factor 2. Neurol. Res. 2013, 35:968-975.
105. Pamplona F.A., Ferreira J., Menezes de Lima O., Duarte F.S., Bento A.F., Forner S., et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:21134-21139.
106. Pruss H., Rosche B., Sullivan A.B., Brommer B., Wengert O., Gronert K., et al. Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial. PLOS ONE 2013, 8:e55859.
107. Svensson C.I., Zattoni M., Serhan C.N. Lipoxins and aspirin-triggered lipoxin stop inflammatory pain processing. J. Exp. Med. 2007, 204:245-252.
108. Sisignano M., Bennett D.L., Geisslinger G., Scholich K. TRP-channels as key integrators of lipid pathways in nociceptive neurons. Prog. Lipid Res. 2014, 53:93-107.
109. Xu Z.-Z., Zhang L., Liu T., Park J.-Y., Berta T., Yang R., et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 2010, 16:592-597.
110. Bang S., Yoo S., Yang T.J., Cho H., Kim Y.G., Hwang S.W. Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br. J. Pharmacol. 2010, 161:707-720.
111. Bang S., Yoo S., Yang T.J., Cho H., Hwang S.W. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br. J. Pharmacol. 2012, 165:683-692.
112. Park C.K., Lü N., Xu Z.Z., Liu T., Serhan C.N., Ji R.R. Resolving TRPV1 and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J. Neurosci. 2011, 31:15072-15085.
113. Xu Z.Z., Liu X.J., Berta T., Park C.K., Lu N., Serhan C.N., et al. Neuroprotectin/protectin D1 protects against neuropathic pain in mice after nerve trauma. Ann. Neurol. 2013, 74:490-495.
114. Park C.K., Xu Z.Z., Liu T., Lu N., Serhan C.N., Ji R.R. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J. Neurosci. 2011, 31:18433-18438.
115. Huang L., Wang C.-F., Serhan C.N., Strichartz G. Enduring prevention and transient reduction of post-operative pain by intrathecal resolvin D1. Pain 2011, 152:557-565.
116. Lima-Garcia J., Dutra R., da Silva K., Motta E., Campos M., Calixto J. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 2011, 164:278-293.
117. Abdelmoaty S., Wigerblad G., Bas D.B., Codeluppi S., Fernandez-Zafra T., El-Awady el S., et al. Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release. PLOS ONE 2013, 8:e75543.
118. Terrando N., Gomez-Galan M., Yang T., Carlstrom M., Gustavsson D., Harding R.E., et al. Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. FASEB J. 2013, 27:3564-3571.
119. Ramsden C.E., Faurot K.R., Zamora D., Suchindran C.M., Macintosh B.A., Gaylord S., et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain 2013, 154:2441-2451.
120. Mirakaj V., Dalli J., Granja T., Rosenberger P., Serhan C.N. Vagus nerve controls resolution and pro-resolving mediators of inflammation. J. Exp. Med. 2014, 211:1037-1048.
121. Klein C.P., Sperotto N.D., Maciel I.S., Leite C.E., Souza A.H., Campos M.M. Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. Neuropharmacology 2014, 86C:57-66.
122. 4 as anti-inflammatory and proresolution mediator in human parturition. FASEB J. 2011, 25:569-575.
123. Xu Z., Zhao J., Zhang H., Ke T., Xu P., Cai W., et al. Spontaneous miscarriages are explained by the stress/glucocorticoid/lipoxin A4 axis. J. Immunol. 2013, 190:6051-6058.
124. 4 as an anti-inflammatory mediator in the human endometrium. Reproduction 2011, 142:345-352.
125. Russell R., Gori I., Pellegrini C., Kumar R., Achtari C., Canny G.O. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J. 2011, 25:4326-4337.
126. Xiong J., Zeng P., Cheng X., Miao S., Wu L., Zhou S., et al. Lipoxin A(4) blocks embryo implantation by controlling estrogen receptor alpha activity. Reproduction 2013, 145:411-420.
127. Motohashi E., Kawauchi H., Endo H., Kondo H., Kitasato H., Kuramoto H., et al. Regulatory expression of lipoxin A4 receptor in physiologically estrus cycle and pathologically endometriosis. Biomed. Pharmacother. 2005, 59:330-338.
128. Canny G.O., Lessey B.A. The role of lipoxin A4 in endometrial biology and endometriosis. Mucosal Immunol. 2013, 6:439-450.
129. Gil-Villa A.M., Norling L.V., Serhan C.N., Cordero D., Rojas M., Cadavid A. Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot. Essent. Fatty Acids 2012, 87:127-134.
130. Jones M.L., Mark P.J., Keelan J.A., Barden A., Mas E., Mori T.A., et al. Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J. Lipid Res. 2013, 54:2247-2254.
131. Yamashita A., Kawana K., Tomio K., Taguchi A., Isobe Y., Iwamoto R., et al. Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth. Sci. Rep. 2013, 3:3113.
132. Weiss G.A., Troxler H., Klinke G., Rogler D., Braegger C., Hersberger M. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis. 2013, 12:89.
133. Kowal-Bielecka O., Kowal K., Distler O., Gay S. Mechanisms of disease: leukotrienes and lipoxins in scleroderma lung disease - insights and potential therapeutic implications. Nat. Clin. Pract. Rheumatol. 2007, 3:43-51.
134. 4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J. Immunol. 2009, 182:5374-5381.
135. Borgeson E., Docherty N.G., Murphy M., Rodgers K., Ryan A., O'Sullivan T.P., et al. Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J. 2011, 25:2967-2979.
136. Qu X., Zhang X., Yao J., Song J., Nikolic-Paterson D.J., Li J. Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J. Pathol. 2012, 228:506-519.
137. Hsiao H.M., Sapinoro R.E., Thatcher T.H., Croasdell A., Levy E.P., Fulton R.A., et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLOS ONE 2013, 8:e58258.
138. Janakiram N.B., Mohammed A., Rao C.V. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011, 30:507-523.
139. Lee H.N. Role of Resolvin D1 in Experimentally Induced Inflammation and Colon Carcinogenesis 2013, Seoul National University, Seoul, South Korea.
140. Lee H.N., Na H.K., Surh Y.J. Resolution of inflammation as a novel chemopreventive strategy. Semin. Immunopathol. 2013, 35:151-161.
141. Panigrahy D. Stimulation of inflammation resolution by resolvins inhibits tumor growth (abstract). 13th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases 2013.
142. Ramon S., Gao F., Serhan C.N., Phipps R.P. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J. Immunol. 2012, 189:1036-1042.
143. Hong S., Lu Y., Yang R., Gotlinger K.H., Petasis N.A., Serhan C.N. Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. J. Am. Soc. Mass Spectrom. 2007, 18:128-144.
144. H2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 2005, 280:43079-43086.
145. Ariel A., Fredman G., Sun Y.-P., Kantarci A., Van Dyke T.E., Luster A.D., et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution via modulation of CCR5 expression. Nat. Immunol. 2006, 7:1209-1216.
146. Settimio R., Clara D.F., Franca F., Francesca S., Michele D. Resolvin D1 reduces the immunoinflammatory response of the rat eye following uveitis. Mediators Inflamm. 2012, 2012:318621.
147. Tian H., Lu Y., Sherwood A.M., Hongqian D., Hong S. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions. Invest. Ophthalmol. Vis. Sci. 2009, 50:3613-3620.
148. + T cells. J. Immunol. 2008, 181:4534-4544.
149. Kim T.H., Kim G.D., Jin Y.H., Park Y.S., Park C.S. Omega-3 fatty acid-derived mediator, resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int. Immunopharmacol. 2012, 14:384-391.
150. Zhang G., Panigrahy D., Mahakian L.M., Yang J., Liu J.Y., Stephen Lee K.S., et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6530-6535.
151. Nording M.L., Yang J., Georgi K., Hegedus Karbowski C., German J.B., Weiss R.H., et al. Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLOS ONE 2013, 8:e76575.
152. Divanovic S., Dalli J., Jorge-Nebert L.F., Flick L.M., Galvez-Peralta M., Boespflug N.D., et al. Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways. J. Immunol. 2013, 191:3347-3357.
153. Hegde S., Kaushal N., Ravindra K.C., Chiaro C., Hafer K.T., Gandhi U.H., et al. Delta12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. Blood 2011, 118:6909-6919.
154. Cipollina C., Salvatore S.R., Muldoon M.F., Freeman B.A., Schopfer F. Clinical generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives (abstract #178). 13th International Conference on Bioactive Lipids in Cancer, Inflammation, and Related Diseases 2013.
155. Morrow J.D., Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 1997, 36:1-21.
156. Ho P.P., Kanter J.L., Johnson A.M., Srinagesh H.K., Chang E.J., Purdy T.M., et al. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci. Transl. Med. 2012, 4:137ra73.
157. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., et al. The human serum metabolome. PLoS ONE 2011, 6:e16957.
158. Mas E., Croft K.D., Zahra P., Barden A., Mori T.A., Resolvins D1 D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 2012, 58:1476-1484.
159. Schottelius A.J., Giesen C., Asadullah K., Fierro I.M., Colgan S.P., Bauman J., et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 2002, 169:7063-7070.
160. Wu S.H., Chen X.Q., Liu B., Wu H.J., Dong L. Efficacy and Safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br. J. Dermatol. 2013, 168:172-178.
161. 4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 1992, 145:1281-1284.
162. Dalli J., Chiang N., Serhan C.N. Identification of sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4753-E4761.
163. Bhavsar P.K., Levy B.D., Hew M.J., Pfeffer M.A., Kazani S., Israel E., et al. Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma. Respir. Res. 2010, 11:71.
164. Yamaguchi H., Higashi N., Mita H., Ono E., Komase Y., Nakagawa T., et al. Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin. Exp. Allergy. 2011, 41:1711-1718.
165. Barnig C., Cernadas M., Dutile S., Liu X., Perrella M.A., Kazani S., et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 2013, 5:174ra26.
166. Fredman G., Oh S.F., Ayilavarapu S., Hasturk H., Serhan C.N., Van Dyke T.E. Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1. PLoS ONE 2011, 6:e24422.
167. Claria J., Nguyen B.T., Madenci A., Ozaki C.K., Serhan C.N. Diversity of lipid mediators in human adipose tissue depots. Am. J. Physiol. Cell Physiol. 2013, 304:C1141-C1149.
168. Giera M., Ioan-Facsinay A., Toes R., Gao F., Dalli J., Deelder A.M., et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim. Biophys. Acta. 2012, 1821:1415-1424.
169. Levy B.D., Kohli P., Gotlinger K., Haworth O., Hong S., Kazani S., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol. 2007, 178:496-502.
170. Rozsasi A., Heinemann A., Keck T. Cyclooxygenase 2 and lipoxin A(4) in nasal polyps in cystic fibrosis. Am. J. Rhinol. Allergy 2011, 25:e251-e254.
171. Vong L., Ferraz J.G., Dufton N., Panaccione R., Beck P.L., Sherman P.M., et al. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS ONE 2012, 7:e39244.
172. El Kebir D., József L., Pan W., Wang L., Petasis N.A., Serhan C.N., et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 2009, 180:311-319.
173. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7671-7676.
174. Wang B., Gong X., Wan J.Y., Zhang L., Zhang Z., Li H.Z., et al. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm. Pharmacol. Ther. 2011, 24:434-441.
175. Bohr S., Patel S.J., Sarin D., Irimia D., Yarmush M.L., Berthiaume F. Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen. 2013, 21:35-43.
176. Gronert K., Maheshwari N., Khan N., Hassan I.R., Dunn M., Schwartzman M.L. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 2005, 280:15267-15278.
177. Biteman B., Hassan I.R., Walker E., Leedom A.J., Dunn M., Seta F., et al. Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J. 2007, 21:2257-2266.
178. Merched A., Ko K., Gotlinger K.H., Serhan C.N., Chan L. Atherosclerosis evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008, 22:3595-3606.
179. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., et al. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J. Exp. Med. 2009, 206:15-23.
180. Kronke G., Katzenbeisser J., Uderhardt S., Zaiss M.M., Scholtysek C., Schabbauer G., et al. 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J. Immunol. 2009, 183:3383-3389.
181. Leedom A.J., Sullivan A.B., Dong B., Lau D., Gronert K. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am. J. Pathol. 2010, 176:74-84.
182. Kronke G., Reich N., Scholtysek C., Akhmetshina A., Uderhardt S., Zerr P., et al. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann. Rheum. Dis. 2012, 71:1081-1087.
183. Tomio K., Kawana K., Taguchi A., Isobe Y., Iwamoto R., Yamashita A., et al. Omega-3 polyunsaturated fatty acids suppress the cystic lesion formation of peritoneal endometriosis in transgenic mouse models. PLOS ONE 2013, 8:e73085.
184. Koltsida O., Karamnov S., Pyrillou K., Vickery T., Chairakaki A.D., Tamvakopoulos C., et al. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol. Med. 2013, 5:762-775.
185. Chiang N., Shinohara M., Dalli J., Mirakaj V., Kibi M., Choi A.M.K., et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique pro-resolving mediator--heme oxygenase-1 circuits. J. Immunol. 2013, 190:6378-6388.
186. Shirey K.A., Lai W., Pletneva L.M., Karp C.L., Divanovic S., Blanco J.C., et al. Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. Mucosal Immunol. 2014, 7:549-557.
187. Blaho V.A., Zhang Y., Hughes-Hanks J.M., Brown C.R. 5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis. J. Immunol. 2011, 186:3076-3084.
188. Bafica A., Scanga C.A., Serhan C., Machado F., White S., Sher A., et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J. Clin. Invest. 2005, 115:1601-1606.
189. Aliberti J., Serhan C., Sher A. Parasite-induced lipoxin A(4) is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 2002, 196:1253-1262.
190. Petri M.H., Laguna-Fernandez A., Tseng C.N., Hedin U., Perretti M., Back M. Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int. J. Cardiol. 2015, 179:370-372.
191. Gobbetti T., Coldewey S.M., Chen J., McArthur S., le Faouder P., Cenac N., et al. Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:18685-18690.
192. Gao L., Faibish D., Fredman G., Herrera B.S., Chiang N., Serhan C.N., et al. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J. Immunol. 2013, 190:689-694.
193. Herrera B.S., Hasturk H., Kantarci A., Freire M.O., Nguyen O., Kansal S., et al. The impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect. Immun. 2014, 10.1128/IAI.02444-14.
194. 4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 2007, 178:3912-3917.
195. Levy B.D., Bonnans C., Silverman E.S., Palmer L.J., Marigowda G., Israel E., et al. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 2005, 172:824-830.
196. Sanak M., Levy B.D., Clish C.B., Chiang N., Gronert K., Mastalerz L., et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 2000, 16:44-49.
197. Peebles R.S. A new horizon in asthma: inhibiting ILC function. Sci. Transl. Med. 2013, 5:174fs7.
198. Gutierrez A.D., Sathyanarayana P., Konduru S., Ye Y., Birnbaum Y., Bajaj M. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis 2012, 223:204-208.
199. Ho K.J., Spite M., Owens C.D., Lancero H., Kroemer A.H., Pande R., et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am. J. Pathol. 2010, 177:2116-2123.
200. Clària J., Dalli J., Yacoubian S., Gao F., Serhan C.N. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J. Immunol. 2012, 189:2597-2605.
201. Zivkovic A.M., Yang J., Georgi K., Hegedus C., Nording M.L., O'Sullivan A., et al. Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations. Metabolomics 2012, 8:1102-1113.
202. Colas R.A., Shinohara M., Dalli J., Chiang N., Serhan C.N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 2014, 307:C39-C54.
203. Yanes O., Clark J., Wong D.M., Patti G.G., Sánchez-Ruiz A., Benton H.P., et al. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 2010, 6:411-417.